Literature DB >> 8305786

So much writing, so little science: a review of 37 years of literature on edetate sodium chelation therapy.

M T Grier1, D G Meyers.   

Abstract

OBJECTIVE: To determine the safety and efficacy of edetate sodium (ethylenediamine tetraacetic acid; EDTA) chelation therapy for atherosclerosis.
METHODS: Literature search using MEDLINE, encompassing 1966 through May 1993. Further references were obtained from articles and books, and from citations obtained from the American Academy of Medical Preventics.
RESULTS: 16 case reports or case series, 2 longitudinal studies, and 3 clinical trials were reviewed, along with testimonials cited in 19 books.
CONCLUSIONS: Little valid scientific evidence is available. Although the postulated mechanisms of action for EDTA are biologically plausible and EDTA appears to be safe, it has not been proven effective. Indeed, the best evidence shows it to be ineffective. Therefore, EDTA chelation therapy should not be used in clinical practice to treat atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8305786     DOI: 10.1177/106002809302701217

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  10 in total

1.  EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy.

Authors:  Gervasio A Lamas; Robin Boineau; Christine Goertz; Daniel B Mark; Yves Rosenberg; Mario Stylianou; Theodore Rozema; Richard L Nahin; L Terry Chappell; Lauren Lindblad; Eldrin F Lewis; Jeanne Drisko; Kerry L Lee
Journal:  Am Heart J       Date:  2014-04-02       Impact factor: 4.749

2.  Dilemmas in care of the elderly.

Authors: 
Journal:  Can Fam Physician       Date:  1996-05       Impact factor: 3.275

Review 3.  Chelation therapy for cardiovascular disease. Review and commentary.

Authors:  M R Lewin
Journal:  Tex Heart Inst J       Date:  1997

4.  The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT).

Authors:  Esteban Escolar; Gervasio A Lamas; Daniel B Mark; Robin Boineau; Christine Goertz; Yves Rosenberg; Richard L Nahin; Pamela Ouyang; Theodore Rozema; Allan Magaziner; Richard Nahas; Eldrin F Lewis; Lauren Lindblad; Kerry L Lee
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-11-19

5.  Design of the Trial to Assess Chelation Therapy (TACT).

Authors:  Gervasio A Lamas; Christine Goertz; Robin Boineau; Daniel B Mark; Theodore Rozema; Richard L Nahin; Jeanne A Drisko; Kerry L Lee
Journal:  Am Heart J       Date:  2012-01       Impact factor: 4.749

6.  Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial.

Authors:  Gervasio A Lamas; Christine Goertz; Robin Boineau; Daniel B Mark; Theodore Rozema; Richard L Nahin; Lauren Lindblad; Eldrin F Lewis; Jeanne Drisko; Kerry L Lee
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

7.  Opinions on chelation therapy in patients undergoing coronary angiography: cross-sectional survey.

Authors:  Hude Quan; P Diane Galbraith; Colleen M Norris; Danielle A Southern; Kathryn King; Marja J Verhoef; Marril L Knudtson; William A Ghali
Journal:  Can J Cardiol       Date:  2007-06       Impact factor: 5.223

8.  Why the NIH Trial to Assess Chelation Therapy (TACT) should be abandoned.

Authors:  Kimball C Atwood; Elizabeth Woeckner; Robert S Baratz; Wallace I Sampson
Journal:  Medscape J Med       Date:  2008-05-13

Review 9.  Potential Role of Metal Chelation to Prevent the Cardiovascular Complications of Diabetes.

Authors:  Rossana Calderon Moreno; Ana Navas-Acien; Esteban Escolar; David M Nathan; Jonathan Newman; John F Schmedtje; Denisse Diaz; Gervasio A Lamas; Vivian Fonseca
Journal:  J Clin Endocrinol Metab       Date:  2019-07-01       Impact factor: 6.134

10.  Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease.

Authors:  Daniel P Cashman
Journal:  Med Hypotheses       Date:  2020-06-26       Impact factor: 1.538

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.